GEN Exclusives

More »

GEN News Highlights

More »
Mar 7, 2007

Aeras Commits $5M to Crucell for Continued TB Research

  • Crucell will receive up to $5 million from Aeras Global TB Vaccine Foundation to support the advanced development of the candidate AdVac-based tuberculosis vaccine.

    "This technology, which is based on one of the most advanced vector delivery systems for induction of cellular immunity, represents an important part of the portfolio of vaccines we are developing against tuberculosis," states Jerald C. Sadoff, president & CEO of Aeras Global TB Vaccine Foundation.

    In March 2004, Aeras and Crucell entered into a collaborative agreement for the development of a PER.C6® and AdVac®-based TB vaccine. The vaccine entered a Phase I trial in October 2006.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?